Biopharma firms trading below cash (Job Market Paper)
Abstract: While almost 100 U.S. biopharma firms went public during the pandemic stock market boom in 2020, half of them experienced scientific failure within a few years after the public offering and have traded below cash due to the scientific failure. The fact that firms are valued below their net cash suggests investors anticipate inefficient continuation and incomplete cash recovery after scientific failure. Motivated by this evidence, I develop and estimate a biopharma start-up financing model to study whether it is rational to provide clinical-stage biopharma firms with so much funding upfront. The optimal contract trades off the cost of inefficient continuation under upfront financing against the dilution cost of follow-on equity issuance with staged capital injections. The model shows that upfront financing is optimal for late-clinical-stage projects, but it cannot fully explain the observed upfront financing for early-clinical-stage projects. In addition, estimated project characteristics suggest that investors funded more innovative and riskier projects during the boom. These findings point to investors’ preference for innovative projects in hot markets, as well as potential speculative motives, as explanations for the upfront financing.
Increased Corporate Cash Holdings and the Role of the Capital Supply
Abstract: This paper emphasizes the role of capital supply in driving higher cash holdings of R&D-intensive firms. By constructing a general equilibrium model, I distinguish the impact of an increase in households’ supply of capital from firms’ precautionary demand for capital. Preliminary result shows that firms’ precautionary demand for capital cannot always lead to higher average cash holdings contrary to findings in the literature.
The Role of the Healthcare Sector in the US Corporate Cash Holdings Puzzle
Abstract: This paper studies how the healthcare sector contributes to the US corporate cash holdings puzzle and approaches the problem from both intensive and extensive margins. By looking at the intensive margin, I explore the changes in the fundamentals of the healthcare sector that make healthcare firms hold more cash on average than firms in other sectors. As for the extensive margin, I first document the increased entry (going public) of healthcare firms and further examine if various performance metrics can rationalize the increased entry. Finally, I consider a simple counterfactual scenario assuming no changes in the healthcare sector (in terms of both margins) and show that roughly 50 percent of the observed positive trend in the average cash holdings of US non-financial public firms can be explained by the healthcare sector.